Welcome to our dedicated page for Cerevel Therapeutics Holdings news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Holdings stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). Formed in 2018 through a partnership between Bain Capital and Pfizer, Cerevel is headquartered in Cambridge, Massachusetts. The company is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases using a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity.
Cerevel's pipeline includes five clinical-stage investigational therapies and several preclinical compounds targeting a range of CNS disorders, such as Parkinson’s disease, Alzheimer’s disease psychosis, epilepsy, schizophrenia, and addiction. The company’s lead programs include:
- Emraclidine: An M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer’s disease psychosis.
- Darigabat: An α2/3/5-selective GABAA receptor PAM currently under development for epilepsy and panic disorder.
- Tavapadon: A D1/D5 partial agonist currently in Phase 3 for the treatment of Parkinson’s disease.
- CVL-871: A D1/D5 partial agonist in development for treatment of dementia-related apathy.
In recent news, Cerevel announced the pricing of its underwritten public offering, where it successfully raised approximately $450 million. Additionally, Cerevel reported positive topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon as an adjunctive therapy to levodopa in Parkinson’s disease. The company is also advancing its early clinical pipeline and discovery programs while exploring new modalities through internal research, external collaborations, or potential acquisitions.
On December 6, 2023, Cerevel announced its acquisition by AbbVie Inc. (NYSE: ABBV). The transaction, valued at approximately $8.7 billion, aims to bolster AbbVie’s neuroscience portfolio with Cerevel’s robust pipeline of therapies. The acquisition is expected to close by mid-2024, subject to regulatory approvals and other customary conditions.
Cerevel continues to drive forward with its mission, leveraging its deep understanding of neurocircuitry and targeted receptor subtype selectivity to develop innovative treatments for neuroscience diseases, ultimately aiming to improve patient outcomes and quality of life.
Cerevel Therapeutics (Nasdaq: CERE) reported its fourth quarter and full year 2020 results on March 24, 2021. The company ended 2020 with $383.6 million in cash, substantially up from $79.6 million in 2019, thanks to a successful go-public transaction. R&D expenses rose to $103.3 million, driven by advancements in clinical trials for drug candidates like tavapadon and darigabat. Looking ahead, 2021 is positioned as a pivotal year with multiple clinical data readouts anticipated and R&D expenses expected to increase.
Cerevel Therapeutics (Nasdaq: CERE) will have its CEO, Tony Coles, participate in a fireside chat at the Stifel 3rd Annual CNS Day on March 31, 2021, at 9:00 a.m. EDT. Investors can access the live webcast in the investor relations section of the Cerevel website. The company focuses on neuroscience diseases and has a diversified pipeline including five clinical-stage therapies for conditions like schizophrenia and epilepsy. Cerevel is committed to advancing its research and potential collaborations or acquisitions.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its fourth quarter and full year 2020 financial results on March 24, 2021, before U.S. markets open. A conference call will follow at 8:00 a.m. EST to discuss the results and business updates. Interested parties can access the call via phone or through a live webcast on the company's investor site. Cerevel is focused on neuroscience diseases, with a pipeline of five clinical-stage therapies targeting conditions such as Parkinson's and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) will participate in the Cowen 41st Annual Health Care Conference on March 3, 2021. The presentation is scheduled for 11:00 a.m. EST and will be available via live webcast on their investor relations website. Cerevel specializes in neuroscience diseases and is advancing multiple clinical-stage therapies for conditions like Parkinson’s, epilepsy, and schizophrenia.
The company emphasizes its unique approach combining neurocircuitry knowledge with receptor selectivity.
Cerevel Therapeutics has announced that darigabat is now the international nonproprietary name for CVL-865, a Phase 2 GABA Positive Allosteric Modulator. The company is hosting a live R&D event to detail its ongoing Phase 2 trials for darigabat in drug-resistant focal epilepsy and acute anxiety. Cerevel plans to file U.S. IND applications in 2021 for its PDE4B and Kappa Opioid Receptor Agonist preclinical programs. Darigabat has been well-tolerated in previous trials, showing effectiveness in epilepsy treatment.
Cerevel Therapeutics has appointed Deval Patrick and Deborah Baron as independent members of its Board of Directors. Patrick, a former Massachusetts governor, brings expertise in the life sciences sector, while Baron serves as senior vice president at Pfizer, leading global business development. CEO Tony Coles expressed optimism about their contributions to Cerevel's goal of becoming a premier neuroscience company. Cerevel focuses on developing innovative treatments for conditions like Parkinson's disease and schizophrenia, boasting a diverse pipeline of clinical-stage therapies.
Cerevel Therapeutics will host a virtual R&D event on January 28, from 9:00 to 11:00 a.m. EST, focusing on CVL-865, a Phase 2 GABA positive allosteric modulator. The presentation will include insights into CVL-865 and preclinical programs.
CVL-865 is currently under investigation in two clinical trials: the REALIZE trial for drug-resistant focal onset seizures, with results expected in 2022, and a Phase 1 trial for acute anxiety, with results anticipated in 2021. The webcast will be available for replay for 90 days.
Cerevel Therapeutics (Nasdaq: CERE) has appointed Dr. Ruth McKernan as an independent board member. A seasoned expert in neuroscience, Dr. McKernan has over 25 years of experience in the pharmaceutical industry, including leadership roles at Pfizer and Merck. She currently works with SV Health Investors, focusing on neurodegenerative disorders. CEO Tony Coles believes her expertise will enhance Cerevel's innovation in therapies for diseases like schizophrenia and Parkinson's. Cerevel aims to establish itself as a premier neuroscience company.
Cerevel Therapeutics (Nasdaq: CERE) will host a live webcast on December 14 from 11:00 a.m. to noon EST, providing a corporate overview and a moderated Q&A session. Presenters include Tony Coles, Ray Sanchez, and John Renger, alongside Kathy Yi as part of the Q&A. Access to the live webcast will be available via the company’s investor relations website, with a replay for 90 days. Cerevel focuses on treating neuroscience diseases and has a pipeline of five clinical-stage therapies for conditions like schizophrenia and Parkinson’s disease.
Cerevel Therapeutics (Nasdaq: CERE) announced that its Chairperson and CEO, Tony Coles, M.D., will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Virtual Conference. The event is scheduled for December 2, 2020, at 3:05 p.m. EST. Interested parties can access the live webcast through the investor relations section of the Cerevel website, where a replay will be available for about 90 days. Cerevel focuses on treating neuroscience diseases with a diversified pipeline of therapies targeting conditions like schizophrenia and epilepsy.
FAQ
What is the current stock price of Cerevel Therapeutics Holdings (CERE)?
What is the market cap of Cerevel Therapeutics Holdings (CERE)?
What does Cerevel Therapeutics Holdings, Inc. specialize in?
When was Cerevel Therapeutics formed?
Where is Cerevel Therapeutics headquartered?
What are some of Cerevel Therapeutics' leading investigational therapies?
What is the significance of Cerevel’s recent Phase 3 TEMPO-3 trial results?
What recent financial achievement has Cerevel accomplished?
What major acquisition was announced involving Cerevel Therapeutics?
What is the expected closing date for the AbbVie acquisition of Cerevel?
What is Cerevel Therapeutics' approach to treating neuroscience diseases?
Who are the contacts for media and investor inquiries at Cerevel Therapeutics?
